Cardiology (all articles)
RCT | Rivaroxaban shows promise compared to Enoxaparin in the acute phase of an acute coronary syndrome
16 Feb, 2023 | 15:20h | UTCInvited Commentary: Rivaroxaban for Patients With Acute Coronary Syndromes—Where Do We Stand? – JAMA Network Open
Commentary on Twitter
The H-REPLACE RCT: short-term rivaroxaban (5mg 2x/day) was noninferior to enoxaparin in safety + efficacy during 6-month follow-up among patients with acute coronary syndrome who missed the primary reperfusion window and before selective revascularization. https://t.co/TIHOwGSWjJ
— JAMA Network Open (@JAMANetworkOpen) February 10, 2023
M-A | Blood pressure lowering effects of B-blockers as add-on or combination therapy
16 Feb, 2023 | 15:10h | UTC
Perspective | A short history of saturated fat: the making and unmaking of a scientific consensus
16 Feb, 2023 | 14:57h | UTC
Commentary from the author on Twitter (thread – click for more)
My latest: "A short history of saturated fat: the making and unmaking of a scientific consensus"
Do saturated fats cause heart disease? The science was always weak. Fear of these fats was started by American Heart Assoc. in 1961 based on a flawed study?https://t.co/J3cOlfzTi6— Nina Teicholz (@bigfatsurprise) December 14, 2022
AHA Statement | Optimizing prepregnancy cardiovascular health improves outcomes for pregnant women, offspring
15 Feb, 2023 | 16:14h | UTCSummary: This statement highlights the need to optimize cardiovascular health before pregnancy to reduce the risk for adverse pregnancy outcomes and cardiovascular disease in mothers and children. It emphasizes the role of clinicians in promoting early cardiovascular health, clinical trials to investigate interventions, and the use of a life course framework to monitor health. By targeting cardiovascular health before pregnancy, interventions can improve health outcomes across generations.*
News Release: Does risk for heart disease start before birth? – American Heart Association
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Cohort Study | Associations between types and sources of dietary carbohydrates and cardiovascular disease risk
15 Feb, 2023 | 16:13h | UTCSummary: This study found that the associations between carbohydrate intake and cardiovascular disease risk depend on the type and source of carbohydrates consumed, with free sugar intake being associated with higher risk of total cardiovascular disease and stroke. Fiber intake was associated with lower risk, and replacing refined grain starch and free sugars with wholegrain starch and non-free sugars may be protective for cardiovascular disease. Free sugar intake was also associated with higher triglycerides and lipoprotein subclasses. As with all observational studies, this study cannot establish causality, but rather suggests associations between carbohydrate intake and cardiovascular disease risk, and the importance of considering the quality of carbohydrates consumed for cardiovascular health.*
News Release: Free sugars associated with higher risk of cardiovascular disease – BioMed Central
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Worsening heart failure: nomenclature, epidemiology, and future directions
15 Feb, 2023 | 16:06h | UTC
Cohort Study | Incidence of acute cardiac events during COVID-19-associated hospitalizations
15 Feb, 2023 | 16:05h | UTC
Cohort Study | Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
15 Feb, 2023 | 15:59h | UTCSummary: The CardioRenal and Metabolic disease (CaReMe) HF study estimated the prevalence, clinical outcomes, and costs of heart failure (HF) across 11 countries using digital healthcare systems. The study found that the prevalence of HF was 1-2%, with the most frequent comorbidities being ischemic heart disease and chronic kidney disease (CKD) stages III– V.
Furthermore, the study revealed that hospital care costs were highest for cardiorenal diseases, even higher than those stemming from atherosclerotic cardiovascular diseases. This emphasizes the urgent need for improved risk management and healthcare planning for patients with HF, particularly those with cardiorenal complications.*
News Release: Up to 2% of adults in Europe, North America, Israel likely have heart failure – BMJ Newsroom
Commentary: Multinational Study Details Contemporary Prevalence, Treatment Strategies of Heart Failure – HCP Live
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
M-A | Risk of bias in randomized clinical trials comparing transcatheter and surgical aortic valve replacement
15 Feb, 2023 | 15:52h | UTCCommentary: Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends – TCTMD
Commentary on Twitter
Trials comparing TAVI vs SAVR show substantial proportions of deviation from assigned treatment, loss to follow-up, and additional procedures, as well as systematic selective imbalance favoring TAVI that might affect internal validity. https://t.co/n7hwTMEPGu
— JAMA Network Open (@JAMANetworkOpen) January 3, 2023
Review | Postoperative atrial fibrillation: from mechanisms to treatment
15 Feb, 2023 | 15:54h | UTCPostoperative atrial fibrillation: from mechanisms to treatment – European Journal of Cardiology
Commentary on Twitter
Postoperative atrial fibrillation: from mechanisms to treatment https://t.co/Alpb9eFRGb @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/s27PGkS49X
— European Society of Cardiology Journals (@ESC_Journals) February 14, 2023
Review | Indications, clinical impact, and complications of critical care transesophageal echocardiography
15 Feb, 2023 | 15:45h | UTC
Retrospective Study | Post-cardiac surgery fungal mediastinitis: clinical features, pathogens and outcome
15 Feb, 2023 | 15:40h | UTCPost-cardiac surgery fungal mediastinitis: clinical features, pathogens and outcome – Critical Care
SCAI expert consensus statement on percutaneous coronary intervention without on-site surgical backup
14 Feb, 2023 | 10:51h | UTCCommentaries:
SCAI Expert Consensus Statement Supports Safety of PCI Without On-Site Surgery – HCP Live
Takayasu Arteritis | JACC Focus Seminar
14 Feb, 2023 | 10:39h | UTCTakayasu Arteritis: JACC Focus Seminar 3/4 – Journal of the American College of Cardiology
Related:
Retrospective Study | Outcomes of percutaneous intervention in patients with Takayasu arteritis
14 Feb, 2023 | 10:38h | UTCRelated:
Takayasu Arteritis: JACC Focus Seminar 3/4 – Journal of the American College of Cardiology
Phase 2 RCT | Aficamten in patients with obstructive hypertrophic cardiomyopathy
14 Feb, 2023 | 10:37h | UTC
Retrospective Cohort | Phenotypes of overdiagnosed Long QT syndrome
14 Feb, 2023 | 10:35h | UTCPhenotypes of Overdiagnosed Long QT Syndrome – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentaries:
Phenotypes of Overdiagnosed Long QT Syndrome – American College of Cardiology
Long QT syndrome overdiagnosis persists – MDedge
Commentary on Twitter
Increased physician & public awareness of LQTS-assoc. warning signs & an increase in #ECG screening programs may contribute to an overdiagnosis of #LQTS.
Authors discuss the top 5 causes of LQTS misdiagnosis & provide guidance to reduce this burden. https://t.co/CDUoiUhihY #JACC pic.twitter.com/BNTXMWQzGP
— JACC Journals (@JACCJournals) February 3, 2023
Updated Guideline | Cardiovascular disease risk assessment and reduction, including lipid modification
13 Feb, 2023 | 12:47h | UTCRelated Guidelines:
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Abbreviated lipid guidelines for clinical practice
13 Feb, 2023 | 12:46h | UTCOriginal Guidelines
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Related:
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation
RCT | Preliminary study on the effects of low-dose colchicine in patients undergoing non-CABG cardiac surgery
13 Feb, 2023 | 12:43h | UTC
Commentary on Twitter
✅Colchicine reduced cardiac injury after cardiac surgery
132 pts randomized to
?0.5 mg of colchicine or placebo in the perioperative periodColchicine compared with placebo
Cardiac makers⬇️
Atrial fibrillation⬇️ (few events, though)?https://t.co/c2mZmvj6kQ#CardioTwitter pic.twitter.com/N3DUjr1WsB
— Yuki Kotani, MD | 小谷 祐樹 (@YukiKotani5) February 8, 2023
M-A | Exercise-based cardiac rehabilitation for coronary heart disease
13 Feb, 2023 | 12:28h | UTC
Resistant hypertension: a stepwise approach
10 Feb, 2023 | 13:58h | UTCResistant hypertension: A stepwise approach – Cleveland Clinic Journal of Medicine
Consensus Statement | Evaluation and management of patients with diabetes and heart failure
10 Feb, 2023 | 13:51h | UTCRelated:
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison – ESC Heart Failure
#ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
POTS and Pregnancy: a review of literature and recommendations for evaluation and treatment
10 Feb, 2023 | 13:37h | UTC
Cohort Study | Adverse pregnancy outcomes and long-term risk of ischemic heart disease in mothers
9 Feb, 2023 | 14:02h | UTCNews Release: Five major adverse pregnancy outcomes associated with long term risks of ischemic heart disease – News Medical/BMJ
Commentary: Complications during pregnancy linked to a higher risk of heart disease, study finds – CNN
Related:
AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk
Cohort Study: Preeclampsia and Cardiovascular Disease
All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease
Gestational Hypertension and Future Risk of Cardiovascular Disease